Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Inventory (2016 - 2025)

Dexcom (DXCM) has disclosed Inventory for 16 consecutive years, with $629.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory rose 15.94% to $629.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $629.1 million, a 15.94% increase, with the full-year FY2025 number at $629.1 million, up 15.94% from a year prior.
  • Inventory was $629.1 million for Q4 2025 at Dexcom, up from $604.1 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $629.1 million in Q4 2025 to a low of $306.7 million in Q4 2022.
  • A 5-year average of $505.0 million and a median of $565.2 million in 2023 define the central range for Inventory.
  • Peak YoY movement for Inventory: fell 11.47% in 2022, then soared 82.46% in 2023.
  • Dexcom's Inventory stood at $351.3 million in 2021, then decreased by 12.7% to $306.7 million in 2022, then soared by 82.46% to $559.6 million in 2023, then dropped by 3.04% to $542.6 million in 2024, then rose by 15.94% to $629.1 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Inventory are $629.1 million (Q4 2025), $604.1 million (Q3 2025), and $570.7 million (Q2 2025).